Cargando…
A Phase-2 NIH-sponsored Randomized Clinical Trial of Rituximab in Scleroderma-associated Pulmonary Arterial Hypertension Did Not Reach Significance for Its Endpoints: End of Story? Not So Fast!
Autores principales: | Zhang, Yongneng, Michelakis, Evangelos D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Thoracic Society
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650784/ https://www.ncbi.nlm.nih.gov/pubmed/33856964 http://dx.doi.org/10.1164/rccm.202103-0612ED |
Ejemplares similares
-
The NIH public access policy did not harm biomedical journals
por: Peterson, A. Townsend, et al.
Publicado: (2019) -
Demystifying the NIH Grant Application Process: The Rest of the Story
por: Horner, Ronnie D.
Publicado: (2007) -
Interstitial lung disease in patients with scleroderma - Treatment with rituximab
por: Muñoz, A, et al.
Publicado: (2010) -
Updating clinical endpoint definitions
por: Hassoun, Paul M., et al.
Publicado: (2013) -
Abstracts of the NIH-FDA Conference “Biomarkers and Surrogate Endpoints: Advancing Clinical Research and Applications”
Publicado: (1998)